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OBJECTIVES This study investigated the possibility of achieving angiogenesis by using gene-modified cells
as a vector.
BACKGROUND Although gene therapy for peripheral circulation disorders has been studied intensively, the
plasmid or viral vectors have been associated with several disadvantages, including unreliable
transfection and uncontrollable gene expression.
METHODS Human hepatocyte growth factor (hHGF) and thymidine kinase (TK) expression plasmids
were serially transfected into NIH3T3 cells, and permanent transfectants were selected
(NIH3T3 hHGF TK). Unilateral hindlimb ischemia was surgically induced in BALB/c
nude mice, and cells were transplanted into the thigh muscles. All effects were assessed at four
weeks.
RESULTS The messenger ribonucleic acid expression and protein production of hHGF were confirmed.
Assay of growth inhibition by ganciclovir revealed that the 50% (median) inhibitory con-
centration of NIH3T3  hHGF  TK was 1,000 times lower than that of NIH3T3 
hHGF. The NIH3T3  hHGF  TK group had a higher laser Doppler blood perfusion
index, higher microvessel density, wider microvessel diameter, and lower rate of hindlimb
necrosis, as compared with the plasmid- and adenovirus-mediated hHGF transfection groups
or the NIH3T3 group. The newly developed microvessels were accompanied by smooth
muscle cells, as well as endothelial cells, indicating that they were on the arteriolar or venular
level. Laser Doppler monitoring showed that the rate of blood perfusion could be controlled
by oral administration of ganciclovir. The transplanted cells completely disappeared in
response to ganciclovir administration for four weeks.
CONCLUSIONS Gene-modified cell transplantation therapy induced strong angiogenesis and collateral vessel
formation that could be controlled externally with ganciclovir. (J Am Coll Cardiol 2004;43:
1915–22) © 2004 by the American College of Cardiology Foundationh
p
d
s
t
w
a
m
f
t
m
p
a
i
c
p
g
c
f
h
t
arowth factors isolated recently, including vascular endo-
helial cell growth factor, fibroblast growth factor, angio-
oietin, and hepatocyte growth factor (HGF), have been
ound to induce strong angiogenesis (1–5). A number of
tudies have reported induction of angiogenesis and collat-
ral vessel formation by gene therapy with these factors in
oth animal experiments and clinical trials. Plasmid or viral
ectors have been used in these therapies (2,6,7), but the
denovirus vector entails some serious problems, such as
llergic reactions or difficulty with repeated treatment,
espite sufficiently high transfection efficiency. Moreover,
lthough plasmid vectors have recently been used in clinical
ettings, have not been associated with allergic reactions,
nd could be used repeatedly, their transfection efficiency
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atient. These gene delivery methods have the common
rawbacks of not being able to choose the target cells and to
electively eliminate the transfected cells once they acquire
he character of abnormal growth. Thus, new methods that
ould provide ideal gene delivery systems have long been
waited.
Regeneration therapy has recently been performed in
any tissues and organs. Various types of cells regenerate
rom embryonic or adult stem cells, and these cells would be
ransplanted into patients. Rapid and sufficient establish-
ent of angiogenesis and collateral vessel formation to
romote the survival and function of the transplanted cells
re especially important in terms of blood supply. We
nvestigated regeneration of cardiomyocytes from adult stem
ells and concluded that blood vessel formation into trans-
lanted cells is crucial to their survival (8). Because angio-
enic gene therapy with plasmid vectors has been insuffi-
ient to induce the rapid and powerful angiogenesis required
or transplantation of the regenerated cells, a new method
as been needed to address this problem.
In the present study, NIH3T3 cells were permanently
ransfected with a novel angiogenic human HGF (hHGF)
nd thymidine kinase (TK) of herpes simplex gene and then
sed as a gene therapy vector. Their effect on blood flow,
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Gene-Modified, Cell-Mediated Angiogenesis May 19, 2004:1915–22ngiogenesis, and collateral formation was investigated in a
urine ischemic hindlimb model (9–11). In this paper, we
eport that gene-modified cells expressing hHGF and TK
nduced strong angiogenesis and collateral vessel formation,
nd that they were easily controlled externally with ganci-
lovir.
ETHODS
ell culture. The NIH3T3 cells were cultured in Dulbec-
o’s modified Eagle’s medium (DMEM), supplemented
ith 10% fetal bovine serum and penicillin (100 g/ml),
treptomycin (250 ng/ml), and amphotericin B (85 g/ml).
table transfection of hHGF and TK genes. The com-
lementary deoxyribonucleic acid (cDNA) of the hHGF
nd TK genes was inserted into the pUC-SR and pGK
xpression vector plasmids, respectively (10–13). pPUR and
cDNA3.1/Hygro() are selection plasmids that confer
uromycin resistance and hygromycin resistance, respec-
ively. After co-transfection of pUC-SR/hHGF and
PUR into the NIH3T3 cells, using the Effectene Reagent
QIAGEN GmbH, Hilden, Germany), the puromycin-
onresistant cells were removed with puromycin (3 g/ml),
nd the hHGF-producing cells were clonally selected
NIH3T3  hHGF). pGK/TK and pcDNA3.1/Hygro()
lasmids were then similarly co-transfected into the
IH3T3  hHGF cells; the hygromycin-nonresistant cells
ere removed with hygromycin (200 g/ml); and both
HGF- and TK-producing cells were clonally selected
NIH3T3  hHGF  TK).
everse transcription-polymerase chain reaction (RT-
CR). Expression of hHGF messenger ribonucleic acid
as analyzed by RT-PCR using the primers that specifically
etect human but not mouse HGF, as previously described
14).
nzyme-linked immunosorbent assay (ELISA) for
HGF. Production of hHGF was determined by ELISA
ith anti-human–specific HGF monoclonal antibodies (In-
titute of Immunology, Tokyo, Japan) (6,15,16).
d.CA-hHGF. The adenoviral vector plasmid pAd.CA-
HGF, which is composed of a cytomegalovirus immediate
arly enhancer, a modified chicken beta-actin promoter, and
Abbreviations and Acronyms
DMEM  Dulbecco’s modified Eagle’s medium
EGFP  enhanced green fluorescent protein
ELISA  enzyme-linked immunosorbent assay
hHGF  human hepatocyte growth factor
IC50  50% (median) inhibitory concentration
LDPI  laser Doppler perfusion image
RT-PCR  reverse transcription-polymerase chain
reaction
SMA  smooth muscle actin
TK  thymidine kinase
vWF  von Willebrand factorHGF cDNA, was constructed by the in vitro ligation rethod (17). The pAd.CA-hHGF plasmid was partially
ut with PacI and then transfected into 293 cells, followed
y culture with 0.5% overlaid agarose--minimal essential
edium (MEM) containing 5% horse serum for 10 to 15
ays. Viral plaques, which had been confirmed by restriction
nzyme analysis and ELISA for hHGF, were propagated in
93 cells, purified by CsCl2 gradient ultracentrifugation
wice, and desalted with a desalting column (18). Viral
articles were calculated by means of optical density at 260
m.
urine model of hindlimb ischemia. All animal experi-
ents were approved by the Animal Care and Use Com-
ittee of Keio University. After anesthetizing male
ALB/c nude mice (eight weeks) with diethyl ether, the
emoral artery was gently isolated, and the proximal portion
as ligated with 7-0 silk ligatures (19,20).
ransplantation of continuously hHGF-producing
IH3T3 cells. The hindlimb ischemic mice (n  192)
ere randomly classified into five groups. The control
roups received 0.2 ml saline only (n  14), 500 g
UC-SR/hHGF plasmids in 0.2 ml saline (n  10), 109
articles Ad.CA-hHGF in 0.2 ml phosphate-buffered sa-
ine (n 10), or NIH3T3 in 0.2 ml DMEM (n 14). The
xperimental group received NIH3T3  hHGF  TK in
.2 ml DMEM (n  144). All injections were given via a
7-gauge needle (21). The numbers of cells transplanted
anged from 104 to 107. They were injected into two
ifferent sites in the ischemic thigh (adductor) skeletal
uscles on postoperative day 1. The direction of injection
as parallel to the muscle fibers. Angiogenesis and collateral
essel formation were assessed at four weeks.
aser Doppler blood perfusion analysis. The blood per-
usion rate in the ischemic (left leg) and normal (right leg)
indlimb was measured with a laser Doppler perfusion image
LDPI) system (Moor Instruments), as described previously
20,22).
istopathology. Frozen sections (4 m) were cut from
issue specimens (23). Immunohistochemical staining for
HGF, endothelial cells, and alpha-smooth muscle actin
SMA) was carried out with anti-human HGF (R&D
ystems Inc., Minneapolis, Minnesota), anti-human von
illebrand factor (vWF)/horseradish peroxidase (HRP),
nd anti-human SMA/HRP (Dakocytomation, Kyoto, Ja-
an), respectively. Sections for staining and counterstaining
ere incubated with 3,3-diaminobenzidine tetrahydrochlo-
ide and Mayer’s hematoxylin solution, respectively. Elastica
an Gieson staining was carried out by the standard
ethod. Paraffin sections (3 m) were cut from tissue
pecimens, and hematoxylin-eosin staining was carried out
y the standard method.
ssay of growth inhibition by ganciclovir in vitro. After
eeding cells on six-well plates (105 cells/well) and culturing
or 24 h, they were exposed to ganciclovir in concentrations
3anging from 0 to 10 g/ml for 72 h (24,25).
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May 19, 2004:1915–22 Gene-Modified, Cell-Mediated Angiogenesisetection of ganciclovir-induced apoptosis with annexin
. Annexin V is an early apoptotic marker. The NIH3T3
hHGF  TK group was exposed to 107 g/ml ganci-
lovir for 48 h, and the apoptotic cells were detected with an
nnexin V-enhanced green fluorescent protein (EGFP)
poptosis detection kit (Medical & Biological Labs Co.
td., Nagaya, Japan) (26).
egulation of transplanted cell growth with ganciclovir
n vivo. We investigated the dose-response relationship of
rowth inhibition by ganciclovir by transplanting NIH3T3
hHGF  TK (107 cells) and administering ganciclovir
wo weeks later. The transplanted mice received different
oses (0, 1, 10, 50, or 80 mg/kg per day) of ganciclovir orally
nce a day for four weeks.
tatistical analysis. The data were processed using Stat-
iew J-4.5 software. Results are reported as the mean value
SE. Comparisons of values among all groups were
erformed by one-way analysis of variance. The Scheffe’s F
est was used to determine the level of significance. The
igure 1. (A) Expression of human hepatocyte growth factor (hHGF)
essenger ribonucleic acid in the hHGF-transfected NIH3T3 cells. The
rimer set of reverse transcription-polymerase chain reaction specifically
etects hHGF but not mouse HGF. pUC-SR/hHGF plasmid and mouse
iver were used as a positive and negative control, respectively. M  the
X174-HaeIII digest. (B) Production of hHGF protein. This ELISA
ystem specifically detects only hHGF because of the lack of cross-
eactivity by the antibodies. Data are expressed as hHGF concentrations
djusted for cell number. Both NIH3T3 hHGF and NIH3T3 hHGF
thymidine kinase (TK) groups expressed hHGF messenger ribonucleic
cid and produced hHGF protein (n  5).robability level accepted for significance was p  0.05. fESULTS
ermanently hHGF-transfected NIH3T3 cells produced
HGF protein. The NIH3T3  hHGF cells were ob-
ained after two weeks of exposure to puromycin, and
IH3T3  hHGF  TK cells were obtained after two
ore weeks of exposure to hygromycin. We confirmed that
oth the NIH3T3 hHGF and NIH3T3 hHGF TK
roups expressed hHGF mRNA and then produced hHGF
rotein at a rate of 17.3  1.4 and 19.1  2.0 pg/106 cells
er 24 h, respectively (Fig. 1).
anciclovir-inhibited cell growth and induced apoptotic
ell death. It is well known that HGF regulates cell
rowth. To determine whether transfection of hHGF af-
igure 2. (A) Influence of hHGF and/or TK genes on cell growth in vitro.
he growth rate of the hHGF-transfected NIH3T3 cells was slightly
igher than that of the nontransfected cells, but TK had no effect on cell
rowth. (circles  NIH3T3; diamonds  NIH3T3  hHGF; squares 
IH3T3  hHGF  TK) (n  3). (B) Growth-inhibitory effect of
anciclovir. The IC50 of ganciclovir for the NIH3T3  hHGF  TK
roup (solid bars) was 1,000 times lower than that for the NIH3T3 
HGF group (open bars) (n  5). (C) Apoptotic cells stained with
nnexin V-EGFP at the cell membrane after exposure to ganciclovir.
bbreviations as in Figure 1.ects the growth of NIH3T3 cells, we counted the numbers
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Gene-Modified, Cell-Mediated Angiogenesis May 19, 2004:1915–22f cells in vitro (Fig. 2A). The growth rate of the hHGF-
ransfected NIH3T3 cells seemed to increase slightly, but
he increase was not significant on day 3. Transfection of
he TK gene had no effect on their growth rate.
Next, we investigated the growth-inhibitory effect of
anciclovir on these cells (Fig. 2B). The IC50 of ganciclovir
or the NIH3T3  hHGF  TK group was 1,000 times
ower than that for the NIH3T3  hHGF group. These
ndings confirmed that the TK plasmid genes had been
ffectively transfected, and that hardly any of the cells that
xpressed the TK gene survived exposure to ganciclovir at a
oncentration of 106 g/ml, which did not affect the control
ells.
Enhanced green fluorescent protein fluorescence was
etected at the membranes of NIH3T3  hHGF  TK
ells after ganciclovir exposure (Fig. 2C), indicating that cell
eath was attributable to apoptosis.
uman HGF-producing cell therapy augmented angio-
enesis and collateral vessel formation. To evaluate
hether transplantation of hHGF-producing cells improves
he perfusion of ischemic hindlimbs, we first determined the
ate of necrosis of the ischemic hindlimb. Necrosis was rated
n a three-grade scale. The rate of necrosis of the foot and
oes in the saline group was 35.7% and 42.9%, respectively.
he rates in the pUC-SR/hHGF group were 20% and
0%, respectively, and in the Ad.CA-hHGF group 10% and
0%, respectively. These therapeutic approaches were effec-
ive in comparison with the saline group, but they were not
ufficient to fully prevent the necrosis. To further ameliorate
imb necrosis, we examined angiogenic gene-modified cell
ransplantation therapy. The NIH3T3 (107 cells) group had
ates of 14.3% and 35.7%, respectively, suggesting that the
ector cell transplantation itself might improve perfusion of
he ischemic limb to some extent. In contrast, the rates in
he NIH3T3  hHGF  TK (107 cells) group were 5.8%
nd 14.5%, respectively (Fig. 3). The rate of necrosis was
urprisingly reduced in the NIH3T3  hHGF  TK
roup, indicating that transplantation of hHGF-producing
ells might be one of the most effective methods of
igure 3. Frequency of necrosis in the ischemic hindlimbs. Severe hind-
imb necrosis was significantly reduced in the NIH3T3  hHGF  TK
roup. Open areas  negative necrosis; lined areas  necrosis on toes;
olid areas  necrosis on foot. Abbreviations as in Figure 1.mproving limb ischemia. tessel density and size. Immunostaining clearly revealed
he presence of numerous vessels in the NIH3T3  hHGF
TK group (Fig. 4A, panel c) and a lower number of
essels in the saline (Fig. 4A, panel a) and NIH3T3 (Fig.
A, panel b) groups. Quantitative analysis revealed that the
essel density in the ischemic region was significantly higher
Fig. 4B), and the minimum diameter of the vWF-positive
essels was significantly greater (Figs. 4A, panel d, and 4C)
n the NIH3T3  hHGF  TK group.
essel maturation. Maturation of the vessels was investi-
ated by staining three consecutive frozen sections of
schemic skeletal muscle. Amazingly, most of the vessels in
he NIH3T3  hHGF  TK group were vWF/-SMA–
ouble positive (Figs. 5A, panels a and b, and 5B). How-
ver, there was no increase in elastic fiber-positive cells, as
ompared with the saline and NIH3T3 groups (Figs. 5A,
anel c, and 5B). These findings showed that NIH3T3 
HGF  TK cell transplantation strongly induced angio-
enesis not only at the capillary level but also at the
icrovessel (arteriole) level, and it caused angiogenesis at
igure 4. (A, panels a to d) Immunohistochemical staining for von
illebrand factor in the triceps muscle of the left calf revealed the presence
f numerous vessels. Vessels were larger and more numerous in the
IH3T3 hHGF TK group (panels c and d) than in the saline (panel
) and NIH3T3 groups (panel b). Scale bars  100 m. (B) The number
f vessels was determined by observation of 20 random fields from 10 mice
2 fields per mouse; *p  0.01). (C) Distribution of the minimum
iameters of the von Willebrand factor-positive vessels (n  25; *p 
.0001). Abbreviations as in Figure 1.he large blood vessel level.
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May 19, 2004:1915–22 Gene-Modified, Cell-Mediated Angiogenesisaser Doppler blood perfusion. The LDPI analysis was
erformed to study subcutaneous blood perfusion. Represen-
ative images are shown in Figure 6A, and quantitative analysis
f blood perfusion is shown in Figure 6B. No blood perfusion
as observed in the hindlimb immediately after femoral artery
igation (Fig. 6A, panel a). Perfusion of the proximal part of
he thigh had recovered at four weeks in the saline and
IH3T3 groups, but perfusion distal to the heel joint had
arkedly decreased (Fig. 6A, panels b and c). In the NIH3T3
hHGF  TK (104 cells) group, perfusion of the ischemic
imb almost recovered to the control (nonischemic) level, but
erfusion distal to the heel was slightly decreased compared
ith the control level (Fig. 6A, panel d). In the NIH3T3 
HGF TK (107 cells) group, perfusion of the ischemic limb
as 118.1% (i.e., much greater than that in the control
indlimb) (Figs. 6A and 6B, panel e). To adjust the recovery of
lood perfusion in the ischemic limb to the appropriate level,
e transplanted NIH3T3  hHGF  TK (107 cells), mon-
tored the LDPI level, and began giving ganciclovir when
lood perfusion reached the control level (two weeks). This
ethod enabled us to adjust the blood perfusion rate in the
schemic limb to the same level as in the control limb (Figs. 6A
nd 6B, panel f).
When the NIH3T3  hHGF  TK cells were trans-
lanted into the normal nonischemic limb, the blood
igure 5. (A, panels a to c) Three consecutive frozen sections of NIH3T3
or vWF and (panel b) -smooth muscle actin (SMA) and (panel c) elas
ompared by using three consecutive frozen sections. Most of the von Will
ice also stained with -SMA (n  20; *p  0.05, †p  0.001, ‡p  0erfusion increased more than that in the control limb. Up go six weeks after transplantation, no evidence of angiosar-
oma or hypervascular tumor was observed in the trans-
lanted limb or other parts of the body (data not shown).
n vivo production of HGF protein. Immunohistochemical
taining demonstrated the production of hHGF protein in
ransplanted NIH3T3  hHGF  TK cells, but not in
ransplanted NIH3T3 cells (Fig. 7A).
ell regulation with ganciclovir and TK. Figure 7B
hows a quantitative analysis of the inhibitory effect of
anciclovir on blood perfusion. At a concentration of 50
g/kg/day of ganciclovir, the blood perfusion was adjusted
n the ischemic limb to the same level as in the control limb,
nd no significant side effects were produced. Histologic
xamination revealed the natural history of the transplanted
ells (Fig. 7C, panels a to c). The transplanted cells formed
mass between the skeletal muscles, which gradually
ncreased in size but did not infiltrate into the skeletal
uscle. Two weeks after transplantation of the NIH3T3 
HGF  TK cells, we began giving ganciclovir orally every
ay for two to four weeks and then examined tissue samples
Fig. 7C, panels d to f). The NIH3T3 hHGF TK cells
radually underwent apoptosis, and by four weeks, no
ransplanted cells could be detected. The surrounding mus-
le cells and the generated vessels were unaffected by
GF  TK transplanted muscle. (panel a) Immunohistochemical staining
n Gieson staining. Scale bars  100 m. (B) Maturation of vessels was
d factor (vWF)-positive vessels in NIH3T3  hHGF  TK transplanted
bbreviations as in Figure 1. hH
tica va
ebran
.01). Aanciclovir.
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Gene-Modified, Cell-Mediated Angiogenesis May 19, 2004:1915–22ISCUSSION
n this study, we assessed angiogenic gene-modified cell
ransplantation therapy with fibroblasts permanently trans-
ected with hHGF and TK genes in a murine hindlimb
schemia model. This therapy had the following merits: 1) it
nduced angiogenesis and collateral vessel formation more
ffectively than with plasmid and viral vectors. 2) The
ombination of TK and ganciclovir allowed the angiogen-
sis to be adjusted by monitoring LDPI. 3) This therapy
ould be stopped at any time desired for any reason. 4)
here was no possibility of the hHGF gene being expressed
n nontarget organs or nontarget cells as a result of leakage
r dispersion of the vectors. If the plasmid vector was
ntegrated into the genome and neoplastic transformation
ccurred, it would be difficult to control cell growth. 5) The
igure 6. (A) Representative laser Doppler perfusion images. (B) Quantit
anel a  Control mouse on postoperative day 1; panels b to f  fo
ransplantation [107 cells]; panel dNIH3T3 hHGF TK transplanta
anel f  beginning two weeks after transplantation of NIH3T3  hHGF
eeks. Oral ganciclovir administration adjusted the blood perfusion rate
ice/group). *p  0.01, †p  0.001 vs. saline, ‡p  0.05, ¶p  0.01 verngiogenic effect can be easily predicted, because the trans- bection efficiency of the gene is always 100%. 6) The cell
ector will be much more effective in patients who require
apid angiogenesis, because plasmid or viral vectors require
week for maximal expression, and the duration of maximal
xpression is short.
Angiogenic gene-modified cell transplantation therapy
as several drawbacks. One is that once the cells are
ransplanted into patients, their growth cannot be con-
rolled. To solve this problem, we double-transfected the
ells with the TK gene, and the results confirmed that
ermanently transfected cells could be killed with ganciclo-
ir after the establishment of angiogenesis and collateral
essel formation. The finding that the IC50 of ganciclovir
or the TK-transfected cells was 1,000 times lower than that
n the nontransfected cells indicated that this system might
analysis of the rate of blood perfusion of the ischemic/nonischemic limb.
eeks after treatment (panel b  saline injection; panel c  NIH3T3
104 cells]; panel eNIH3T3 hHGF TK transplantation [107 cells];
K (107 cells), ganciclovir (50 mg/kg/day) was administered orally for four
ischemic limb to the same level as that of the nonischemic limb (eight
IH3T3. Abbreviations as in Figure 1.ative
ur w
tion [
 T
of the
sus Ne capable of being used in clinical settings.
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May 19, 2004:1915–22 Gene-Modified, Cell-Mediated AngiogenesisWe used NIH3T3, a fibroblast line derived from fetal
IH/Swiss mice, for the following reasons: 1) the transfec-
ion efficiency of the plasmid is high; and 2) their growth
ate is relatively high in vitro, making it easy to expand the
ells. However, their growth rate in vivo is not as high as
hat of carcinoma cell lines, probably because NIH3T3 cells
ave a mechanism of growth inhibition by cell-cell contact.
o apply this method in clinical medicine, the selection of
human cell line will be requried. Considering the time and
ost for preparation of the cells, an autograft might require
long time and be expensive. It took at least two months to
repare the hHGF– and TK–double-transfected cells, and
number of additional experiments were needed to confirm
heir effectiveness and safety. We think that allograft cells
hould be used to prepare gene-modified cells. In view of
he time, cost, effectiveness, and safety of the cells, allografts
ould be much better than autografts.
igure 7. (A) Immunohistochemical staining for hHGF in transplanted N
keletal muscle. Scale bars  50 m. (B) The NIH3T3  hHGF  TK
anciclovir were administered for another four weeks. (C) Hematoxylin-e
hHGF  TK (107) cells is shown. (Panels d to f) Beginning two week
wo to four weeks. The cells had completely disappeared after four weeks of
bbreviations as in Figure 1.Regenerative medicine has recently been the subject of mnvestigations in many fields, and a number of regenerative
ells have been established. The authors have reported that
egenerative cardiomyocytes can be generated from marrow
esenchymal stem cells, and transplantation of the regen-
rated cells will be examined in various organs. One of the
easons why we are considering angiogenic gene-modified
ell transplantation therapy is the need for a rapid blood
upply to the transplanted cells. To achieve that goal, we can
o-transplant target organs with these gene-modified cells
n combination with the regenerated cells. Once the blood
upply has become established, the angiogenic cells are no
onger needed, and they can be eliminated by ganciclovir.
Bone marrow mononuclear cells have recently been used
o induce angiogenesis as a means of treating arteriosclerosis
bliterans (27). Although bone marrow mononuclear cells
ontain endothelial cells, the population of endothelial
rogenitor cells is 1%. The effectiveness of this therapy
T3 cells (panel a) and NIH3T3  hHGF  TK cells (panel b) in the
7) cells were transplanted, and two weeks later, various concentrations of
taining. (Panels a to c) The natural history of the transplanted NIH3T3
r transplantation, ganciclovir (50 mg/kg/day) was administered orally for
iclovir treatment. Arrows indicate the microvessels. Scale bars  100 m.IH3
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ononuclear cells produce various cytokines and angiogenic
rowth factors. The advantage of angiogenic therapy with
one marrow mononuclear cell autografts is that the cells do
ot undergo immunorejection. The drawback of this ther-
py is that the cells may contain a variety of types of cells,
uch as osteogenic or chondrogenic stem cells, or induce
nflammation by secreting cytokines. Using angiogenic
ene-modified cells avoids the problem of transplanting
ifferent types of cells; however, the efficiency and safety of
his procedure needs to be fully investigated before clinical
pplication can become a reality.
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